

# Jennifer B Pierson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6965396/publications.pdf>

Version: 2024-02-01

15  
papers

914  
citations

759233

12  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

1185  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | The Challenges of Predicting Drug-Induced QTc Prolongation in Humans. <i>Toxicological Sciences</i> , 2022, 187, 3-24.   | 3.1 | 13        |
| 2  | Can We Panelize Seizure?. <i>Toxicological Sciences</i> , 2021, 179, 3-13.   | 3.1 | 9         |
| 3  | Use of the ZDF rat to model dietary fat induced hypercoagulability is limited by progressive and fatal nephropathy. <i>Journal of Pharmacological and Toxicological Methods</i> , 2021, 107, 106933.   | 0.7 | 6         |
| 4  | Echocardiographic and hemodynamic indices of myocardial contractility simultaneously evaluated in telemetered beagle dogs: A HESI-sponsored cross-company evaluation. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020, 105, 106897.   | 0.7 | 1         |
| 5  | Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019, 99, 106612.  | 0.7 | 26        |
| 6  | Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms. <i>Frontiers in Pharmacology</i> , 2019, 10, 884.  | 3.5 | 20        |
| 7  | Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes. <i>Frontiers in Pharmacology</i> , 2019, 10, 934. | 3.5 | 30        |
| 8  | Assessing Drug-Induced Long QT and Proarrhythmic Risk Using Human Stem-Cell-Derived Cardiomyocytes in a Ca <sup>2+</sup> Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites. <i>Toxicological Sciences</i> , 2019, 170, 345-356.   | 3.1 | 21        |
| 9  | A Proof-of-Concept Evaluation of JTPc and Tp-Tec as Proarrhythmia Biomarkers in Preclinical Species: A Retrospective Analysis by an HESI-Sponsored Consortium. <i>International Journal of Toxicology</i> , 2019, 38, 23-32.   | 1.2 | 12        |
| 10 | Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study. <i>Toxicological Sciences</i> , 2018, 164, 550-562.  | 3.1 | 90        |
| 11 | Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium. <i>British Journal of Pharmacology</i> , 2018, 175, 606-617.   | 5.4 | 44        |
| 12 | International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. <i>Cell Reports</i> , 2018, 24, 3582-3592.  | 6.4 | 254       |
| 13 | Non-Lethal Endotoxin Injection: A Rat Model of Hypercoagulability. <i>PLoS ONE</i> , 2017, 12, e0169976.   | 2.5 | 28        |
| 14 | The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative – Update on progress. <i>Journal of Pharmacological and Toxicological Methods</i> , 2016, 81, 15-20.  | 0.7 | 335       |
| 15 | A public-private consortium advances cardiac safety evaluation: Achievements of the HESI Cardiac Safety Technical Committee. <i>Journal of Pharmacological and Toxicological Methods</i> , 2013, 68, 7-12.   | 0.7 | 25        |